Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis.

about

Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q55000881

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Certolizumab pegol in a hetero ...... o-severe rheumatoid arthritis.

@en

Certolizumab pegol in a hetero ...... o-severe rheumatoid arthritis.

@nl

type

Item

label

Certolizumab pegol in a hetero ...... o-severe rheumatoid arthritis.

@en

Certolizumab pegol in a hetero ...... o-severe rheumatoid arthritis.

@nl

prefLabel

Certolizumab pegol in a hetero ...... o-severe rheumatoid arthritis.

@en

Certolizumab pegol in a hetero ...... o-severe rheumatoid arthritis.

@nl

P1476

Certolizumab pegol in a hetero ...... o-severe rheumatoid arthritis.

@en

P2093

Analia Dellepiane

http://www.w3.org/2001/XMLSchema#string

Carlos Baruzzo

http://www.w3.org/2001/XMLSchema#string

Cristian Alejandro Benítez

http://www.w3.org/2001/XMLSchema#string

Enrique R Soriano

http://www.w3.org/2001/XMLSchema#string

Gabriela Salvatierra

http://www.w3.org/2001/XMLSchema#string

Rodrigo Garcia Salinas

http://www.w3.org/2001/XMLSchema#string

P2860

Certolizumab pegol

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

The pathogenesis of rheumatoid arthritis

Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised phase III clinical trial.

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients.

Future therapeutic targets in rheumatoid arthritis?

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.

Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

P304

FSO289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/FSOA-2017-0149

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29682324

http://www.w3.org/2001/XMLSchema#string

P932

5905631

http://www.w3.org/2001/XMLSchema#string